Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel Free LXRX Stock Alerts

Lexicon Pharmaceuticals (LXRX) Earnings Date, Estimates & Call Transcripts

Lexicon Pharmaceuticals logo
$2.32 -0.02 (-0.85%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$2.34 +0.02 (+0.65%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Lexicon Pharmaceuticals Earnings Summary

Lexicon Pharmaceuticals announced Q2 2026 earnings on August 6, 2026, reporting an EPS of -$0.06, which missed the consensus estimate of -$0.05 by $0.01. Quarterly revenue was reported to be $0.69 million, below the consensus estimate of $3.99 million. With a trailing EPS of -$0.15, Lexicon Pharmaceuticals' earnings are expected to decrease next year, from ($0.17) to ($0.23) per share.

Latest Q2
Earnings Date
Aug. 6Estimated
Consensus EPS
(Aug. 6)
-$0.05
Actual EPS
(Aug. 6)
-$0.06 Missed By -$0.01
Actual Revenue
(Aug. 6)
$0.69M

Q2 2026 Earnings Resources

Slide Deck

Lexicon Pharmaceuticals' Q2 2026 Slide DeckFull Screen Slide Deck
Powered by Quartr
Get Lexicon Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexicon Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

LXRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LXRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Lexicon Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.06-$0.06-$0.06
Q2 20261-$0.05-$0.05-$0.05
Q3 20261-$0.04-$0.04-$0.04
Q4 20261-$0.03-$0.03-$0.03

Lexicon Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026-$0.0502-$0.06 -$0.0098-$0.07$3.99M$0.69M
5/7/2026Q1 2026-$0.04-$0.0026+$0.0374-$9.79M$21.10M
3/5/2026Q4 2025-$0.07-$0.04+$0.03-$0.04$3.14M$5.49M
11/6/2025Q3 2025-$0.07-$0.04+$0.03-$0.04$5.81M$14.18M
8/6/2025Q2 2025-$0.08$0.01+$0.09$0.01$4.87M$28.87M
5/13/2025Q1 2025-$0.10-$0.07+$0.03-$0.07$1.26M$1.26M
3/6/2025Q4 2024-$0.11-$0.09+$0.02-$0.09$6.48M$26.55M
11/12/2024Q3 2024-$0.17-$0.18 -$0.01-$0.18$3.14M$1.75M

Lexicon Pharmaceuticals Earnings - Frequently Asked Questions

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earning data on Thursday, August 6, 2026. Learn more on LXRX's earnings history.

In the previous quarter, Lexicon Pharmaceuticals (NASDAQ:LXRX) missed the analysts' consensus estimate of ($0.05) by $0.01 with a reported earnings per share (EPS) of ($0.06). Learn more on analysts' earnings estimate vs. LXRX's actual earnings.

The conference call for Lexicon Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Lexicon Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Lexicon Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a recorded annual revenue of $49.80 million.

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a recorded net income of -$50.34 million. LXRX has generated -$0.15 earnings per share over the last four quarters.

Lexicon Pharmaceuticals' earnings are expected to decrease from ($0.17) per share to ($0.23) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:LXRX is sourced from Fiscal.ai, with the most recent quarter reported on 8/6/2026. New results are added as companies report their earnings.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Elon admits defeat
Elon Musk just called Anthropic the clear leader in AI, admitting its Mythos model surpasses anything he's bui...
Weiss Ratings | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel